Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Gallium ga 68 FAP-CHX** is a **fibroblast activation protein-targeted PET radiotracer** designed for **diagnostic PET/CT imaging** of tumors with FAP-expressing cancer-associated fibroblasts in the tumor microenvironment. It consists of the FAP-targeting small-molecule tracer FAP-CHX labeled with **gallium-68**, enabling visualization of FAP-positive stromal elements in cancer. Public sources verify a clinical study sponsored by **The First Hospital of Fujian Medical University** evaluating its safety, biodistribution, pharmacokinetics, radiation dosimetry, and diagnostic performance in patients with various solid tumors, including head-to-head comparison with **68Ga-FAPI-04** or **18F-FDG** PET/CT. This agent is a **diagnostic radiopharmaceutical**, not a therapeutic radioligand.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallium ga 68 FAP-CHX.